PIPELINE
-
HOME
- R&D
- PIPELINE
- OVERVIEW
OVERVIEW
| Pipeline | Indication | Development Phase | ||||
|---|---|---|---|---|---|---|
| Hit to Lead | Candidate | Preclinical | Phase 1 | Phase 2 | ||
| EFL-101 | Neurodegenerative disease |
|
||||
| EFL-301 | Fibrosis |
|
||||
| EFL-501 | Muscle wasting disease |
|
||||
| EFL-701 | Peptide drug |
|
||||
-
EFL-101 Neurodegenerative disease
Development Phase Hit to Lead Candidate Preclinical Phase 1 Phase 2 -
EFL-301 Fibrosis
Development Phase Hit to Lead Candidate Preclinical Phase 1 Phase 2 -
EFL-501 Muscle wasting disease
Development Phase Hit to Lead Candidate Preclinical Phase 1 Phase 2 -
EFL-701EFL-701
Development Phase Hit to Lead Candidate Preclinical Phase 1 Phase 2
eFlask Co., Ltd. (13524) 184, Pangyoyeok-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of KoreaTEL : 82-31-707-8356 E-mail : info@eflask.co.krCopyright ⓒ eFlask. All Rights Reserved.